Business Description
![Novo Nordisk A/S Novo Nordisk A/S logo](https://static.gurufocus.com/logos/0C00000BWS.png?14)
Novo Nordisk A/S
NAICS : 325412
SIC : 2836
ISIN : DK0062498333
Share Class Description:
OCSE:NOVO B: Class BCompare
Compare
Traded in other countries / regions
NOVO B.DenmarkNVO.USA0QIU.UKNOV.GermanyN1VO34.BrazilNOVOB.MexicoNNO2.AustriaNOV.Bulgaria IPO Date
1993-11-23Description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.35 | |||||
Equity-to-Asset | 0.33 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | 0.22 | |||||
Interest Coverage | 45.17 | |||||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 14.12 | |||||
Beneish M-Score | -2.28 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 24 | |||||
3-Year EBITDA Growth Rate | 26.3 | |||||
3-Year EPS without NRI Growth Rate | 26 | |||||
3-Year FCF Growth Rate | 34.6 | |||||
3-Year Book Growth Rate | 21.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 24.58 | |||||
Future 3-5Y Total Revenue Growth Rate | 21.35 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.77 | |||||
9-Day RSI | 28.86 | |||||
14-Day RSI | 33.29 | |||||
6-1 Month Momentum % | 37.57 | |||||
12-1 Month Momentum % | 89.82 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.7 | |||||
Quick Ratio | 0.5 | |||||
Cash Ratio | 0.06 | |||||
Days Inventory | 289.24 | |||||
Days Sales Outstanding | 85.53 | |||||
Days Payable | 168.5 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.07 | |||||
Dividend Payout Ratio | 0.47 | |||||
3-Year Dividend Growth Rate | 18.1 | |||||
Forward Dividend Yield % | 1.45 | |||||
5-Year Yield-on-Cost % | 1.89 | |||||
3-Year Average Share Buyback Ratio | 1.7 | |||||
Shareholder Yield % | 1.72 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 84.65 | |||||
Operating Margin % | 44.8 | |||||
Net Margin % | 36.55 | |||||
FCF Margin % | 20.6 | |||||
ROE % | 95.22 | |||||
ROA % | 30.91 | |||||
ROIC % | 29.84 | |||||
ROC (Joel Greenblatt) % | 137.45 | |||||
ROCE % | 88.19 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 44.29 | |||||
Forward PE Ratio | 39.37 | |||||
PE Ratio without NRI | 44.29 | |||||
Shiller PE Ratio | 81.48 | |||||
Price-to-Owner-Earnings | 41.59 | |||||
PEG Ratio | 2.53 | |||||
PS Ratio | 16.18 | |||||
PB Ratio | 39.77 | |||||
Price-to-Tangible-Book | 100.18 | |||||
Price-to-Free-Cash-Flow | 78.78 | |||||
Price-to-Operating-Cash-Flow | 42.36 | |||||
EV-to-EBIT | 34.2 | |||||
EV-to-Forward-EBIT | 29.99 | |||||
EV-to-EBITDA | 31.3 | |||||
EV-to-Forward-EBITDA | 27.48 | |||||
EV-to-Revenue | 16.01 | |||||
EV-to-Forward-Revenue | 13.52 | |||||
EV-to-FCF | 78.39 | |||||
Price-to-Projected-FCF | 5.21 | |||||
Price-to-DCF (Earnings Based) | 2.07 | |||||
Price-to-DCF (FCF Based) | 3.75 | |||||
Price-to-Median-PS-Value | 1.95 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.41 | |||||
Price-to-Graham-Number | 14.04 | |||||
Earnings Yield (Greenblatt) % | 2.93 | |||||
FCF Yield % | 1.29 | |||||
Forward Rate of Return (Yacktman) % | 19.57 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novo Nordisk A/S Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 244,243 | ||
EPS (TTM) (kr) | 19.905 | ||
Beta | 1.02 | ||
Volatility % | 17.84 | ||
14-Day RSI | 33.29 | ||
14-Day ATR (kr) | 23.011942 | ||
20-Day SMA (kr) | 953.015 | ||
12-1 Month Momentum % | 89.82 | ||
52-Week Range (kr) | 527.3 - 1033.2 | ||
Shares Outstanding (Mil) | 4,453.02 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 8 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Novo Nordisk A/S Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Novo Nordisk A/S Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Novo Nordisk A/S Frequently Asked Questions
What is Novo Nordisk A/S(OCSE:NOVO B)'s stock price today?
The current price of OCSE:NOVO B is kr873.70. The 52 week high of OCSE:NOVO B is kr1033.20 and 52 week low is kr527.30.
When is next earnings date of Novo Nordisk A/S(OCSE:NOVO B)?
The next earnings date of Novo Nordisk A/S(OCSE:NOVO B) is 2024-08-07.
Does Novo Nordisk A/S(OCSE:NOVO B) pay dividends? If so, how much?
The Dividend Yield %  of Novo Nordisk A/S(OCSE:NOVO B) is 1.07% (As of Today), Highest Dividend Payout Ratio of Novo Nordisk A/S(OCSE:NOVO B) was 0.62. The lowest was 0.33. And the median was 0.46. The  Forward Dividend Yield % of Novo Nordisk A/S(OCSE:NOVO B) is 1.45%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |